Date of Presentation

5-4-2023 12:00 AM

College

School of Osteopathic Medicine

Poster Abstract

Autism Spectrum Disorder (ASD) and congenital heart defects (CHD) are conditions that both confer an immense increase in standard of care, and utilization of medical resources addressing comorbidities. One shared symptom that has been consistently cited is inflammation. This review sought to explore the levels of Tumor Necrosis Factor-𝞪 (TNF-𝞪) and Interleukin-6 (IL-6) between patients diagnosed as having either ASD or CHD. By compiling published data containing the mean values of these two inflammatory markers within these populations, it was shown that while both have significantly elevated levels compared to a phenotypically normal demographic, there is no significant difference between IL-6 levels in ASD vs. CHD patients. However, there are significantly higher levels of TNF-𝞪 in CHD patients compared to ASD patients. Understanding the relationship of inflammatory markers would help guide better treatments and outcomes in ASD population, especially to those with CHD.

Keywords

Autism Spectrum Disorder, Congenital Heart Defect, Tumor Necrosis Factor-alpha, Interleukin-6, Biomarkers, Epidemiologic Methods

Disciplines

Analytical, Diagnostic and Therapeutic Techniques and Equipment | Cardiology | Cardiovascular Diseases | Clinical Epidemiology | Communication Sciences and Disorders | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Medicine and Health Sciences | Social and Behavioral Sciences

Document Type

Poster

Share

COinS
 
May 4th, 12:00 AM

Inflammatory Marker Levels among Patients Diagnosed with Autism Spectrum Disorder and Congenital Heart Defects

Autism Spectrum Disorder (ASD) and congenital heart defects (CHD) are conditions that both confer an immense increase in standard of care, and utilization of medical resources addressing comorbidities. One shared symptom that has been consistently cited is inflammation. This review sought to explore the levels of Tumor Necrosis Factor-𝞪 (TNF-𝞪) and Interleukin-6 (IL-6) between patients diagnosed as having either ASD or CHD. By compiling published data containing the mean values of these two inflammatory markers within these populations, it was shown that while both have significantly elevated levels compared to a phenotypically normal demographic, there is no significant difference between IL-6 levels in ASD vs. CHD patients. However, there are significantly higher levels of TNF-𝞪 in CHD patients compared to ASD patients. Understanding the relationship of inflammatory markers would help guide better treatments and outcomes in ASD population, especially to those with CHD.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.